Works matching IS 25233548 AND DT 2021 AND VI 41 AND IP 2

Results: 10

Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study.

Published in:

Cancer Communications, 2021, v. 41, n. 2, p. 171, doi. 10.1002/cac2.12135

By:

Hong, Ruoxi;
Xia, Wen;
Wang, Liye;
Lee, Kaping;
Lu, Qianyi;
Jiang, Kuikui;
Li, Shengfeng;
Yu, Jinquan;
Wei, Jin;
Tang, Weijia;
Zhou, Danyang;
An, Xin;
Huang, Jiajia;
Xue, Cong;
Bi, Xiwen;
Shi, Yanxia;
Yuan, Zhongyu;
Xu, Fei;
Wang, Shusen

Publication type:

Article

High‐throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion.

Published in:

Cancer Communications, 2021, v. 41, n. 2, p. 192, doi. 10.1002/cac2.12133

By:

Song, Zhengbo;
Xu, Chunwei;
Pu, Xingxiang;
Zhu, Youcai;
Wang, Wenxian;
Li, Xingliang;
Gao, Yanqiu;
Zhu, Wenliang;
He, Yunwei;
Wu, Lin;
Mao, Li;
Chen, Li;
Chen, Ming

Publication type:

Article

RNF114 suppresses metastasis through regulation of PARP10 in cervical cancer cells.

Published in:

Cancer Communications, 2021, v. 41, n. 2, p. 187, doi. 10.1002/cac2.12132

By:

Zhao, Yahui;
Liang, Xiao;
Wei, Li;
Liu, Yao;
Liu, Juan;
Feng, Huan;
Zheng, Fen;
Wang, Ying;
Ma, Haijie;
Wu, Jiaxue

Publication type:

Article

Dicer‐independent snRNA/snoRNA‐derived nuclear RNA 3 regulates tumor‐associated macrophage function by epigenetically repressing inducible nitric oxide synthase transcription.

Published in:

Cancer Communications, 2021, v. 41, n. 2, p. 140, doi. 10.1002/cac2.12131

By:

Shi, Yang;
Shi, Qingzhu;
Shen, Qicong;
Zhang, Qian;
Cao, Xuetao

Publication type:

Article

S100A8 promotes epithelial‐mesenchymal transition and metastasis under TGF‐β/USF2 axis in colorectal cancer.

Published in:

Cancer Communications, 2021, v. 41, n. 2, p. 154, doi. 10.1002/cac2.12130

By:

Li, Si;
Zhang, Jun;
Qian, Senmi;
Wu, Xuesong;
Sun, Liang;
Ling, Tianyi;
Jin, Yao;
Li, Wenxiao;
Sun, Lichao;
Lai, Maode;
Xu, Fangying

Publication type:

Article

Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer.

Published in:

Cancer Communications, 2021, v. 41, n. 2, p. 91, doi. 10.1002/cac2.12129

By:

Huang, Hai‐Ming;
Li, Hai‐Xia

Publication type:

Article

Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors.

Published in:

Cancer Communications, 2021, v. 41, n. 2, p. 183, doi. 10.1002/cac2.12128

By:

Yang, Dafu;
Li, Dan;
Dai, Zhaoxia;
Ma, Yutong;
Ou, Qiuxiang;
Wu, Xue;
Cui, Saiqiong

Publication type:

Article

CRISPR/Cas9 screening identifies a kinetochore‐microtubule dependent mechanism for Aurora‐A inhibitor resistance in breast cancer.

Published in:

Cancer Communications, 2021, v. 41, n. 2, p. 121, doi. 10.1002/cac2.12125

By:

Chen, Ailin;
Wen, Shijun;
Liu, Fang;
Zhang, Zijian;
Liu, Meiling;
Wu, Yuanzhong;
He, Bin;
Yan, Min;
Kang, Tiebang;
Lam, Eric W‐F;
Wang, Zifeng;
Liu, Quentin

Publication type:

Article

LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer.

Published in:

Cancer Communications, 2021, v. 41, n. 2, p. 109, doi. 10.1002/cac2.12108

By:

Tan, Yue‐Tao;
Lin, Jin‐Fei;
Li, Ting;
Li, Jia‐Jun;
Xu, Rui‐Hua;
Ju, Huai‐Qiang

Publication type:

Article

Issue Information.

Published in:: Cancer Communications, 2021, v. 41, n. 2, p. 89, doi. 10.1002/cac2.12054
Publication type:: Article